Overview

TXA in Spine Surgery

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
As tranexamic acid (TXA) becomes more prevalent, all patients are receiving the same dose and method of delivery regardless of their pre-operative risk of transfusion. Therefore, the aim of the study is to determine whether or not repeated dosing of oral or a different method of delivery like intravenous (IV) TXA reduces the post-operative reduction in hemoglobin, hematocrit, number of transfusions, and postoperative blood loss following open spine surgery.
Phase:
N/A
Details
Lead Sponsor:
Rush University Medical Center
Treatments:
Tranexamic Acid